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1. Introduction 
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and represents 
the third cause of mortality among deaths from cancer (Semela & Heim, 2011; EI-Serag & 
Rudolph, 2007; Yuen et al, 2009; Lodato et al, 2006; Hainaut & Boyle, 2008). There are 
upwards of 600, 000 new cases each year in Asia and sub-Saharan Africa, where populations 
suffer both from a high prevalence of hepatitis B virus (HBV) infection and largely 
uncontrolled aflatoxin exposure in food, and more than 200, 000 HCC-related deaths 
annually in the People’s Republic of China alone (Kew, 2002; Wang et al, 2002). Aflatoxins 
may play a causative role in 5%-28% of all global HCC cases (Liu & Wu, 2010). 
Aflatoxin is a kind of mycotoxins produced by the mold Aspergillus flavus, which can be 
found in legumes, corns, soybeans, rice, milk, and cheese throughout their lives. Aflatoxin 
B1 (AFB1) is regarded as a class I carcinogen by the World Health Organization (Henry et al, 
2001; López et al, 2002). Aflatoxin B1, the most commonly occurring and potent of the 
aflatoxins is associated with a specific AGG to AGT transversion mutation at codon 249 of 
the p53 gene in human HCC, providing mechanistic support to a causal link between 
exposure and disease (Goldman & Shields, 2003; Sugimura, 2000; Wild & Montesano, 2009). 
Prospective epidemiological studies have shown a more than multiplicative interaction 
between HBV and aflatoxins in terms of HCC risk. In this chapter, the available evidence for 
the mechanism of aflatoxin with HBV-infection in HCC will be reviewed. 
2. Mechanisms of aflatoxins in HCC 
Aflatoxins, first described in the early 1960s, are the most toxic and carcinogenic compounds 
among the known mycotoxins. They are produced by several Aspergillus species and 
consist of at least 16 structurally related furanocoumarins, of which AFB1, AFB2, AFG1, and 
AFG2 are the four most abundant aflatoxins. The designation B and G came from the Blue or 
Green fluorescence emitted by these compounds under long-wave ultraviolet light, 
respectively (McLean & Dutton, 1995). Human exposure to aflatoxins is mainly through 
consumption of contaminated staples, such as maize and pea-nuts. Contaminations are 
often the result of inappropriate storage of grain, which leads to the infestation by aflatoxin-
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producing fungi (Williams et al, 2004). Liver is the primary target organ for acute and 
chronic injury. Ingestion of high doses of aflatoxin over a short time period can result in 
acute aflatoxicosis, with symptoms such as hemorrhagic necrosis of the liver, bile duct 
proliferation, edema and lethargy (Williams et al, 2004). Chronic exposure to low or 
moderate doses of aflatoxin may lead to the development of HCC. 
AFB1 is a potent human carcinogen (IARC, 1993), which occurs in the low or sub 
micrograms per kilogram range and is regulated by legislation in the European Union (EU) 
at 2 μg/kg in foods for direct human consumption (European Community, 2006). Several 
studies have evaluated an association between the risk for HCC and exposure to AFB1. A 
prospective case-control study from China mainland showed that individuals with the 
presence of urinary aflatoxin biomarkers had a significantly increased risk of HCC after 
adjusting for HBV surface antigen (HBsAg) seropositivity and cigarette smoking (Qian et al, 
1994). These data were further supported by a community-based cohort study from Taiwan 
which found that elevated AFB1 exposure measured by detectable AFB1-albumin adducts 
was an independent risk factor for HCC after adjustment for other important confounding 
factors (odds risk : 5.5, 95% confidence interval : 1.2-24.5) ( Chen et al, 1996a). 
2.1 Metabolism of AFB1 
The cytochrome P450 (CYP) enzymes are a superfamily of hemeproteins that are important 
in the oxidative, peroxidative and reductive metabolism of endogenous compounds and 
participate in the chemical carcinogenesis process (Gonzalez & Lee, 1996). AFB1 is activated 
by CYP enzymes, mainly CYP 1A2 and 3A4, to form four major metabolites: AFM1, AFQ1, 
AFB1-endo-8, 9-epoxide and AFB1-exo-8, 9-epoxide. AFM1 and AFQ1 are polarmolecules; 
AFB1-endo-8, 9-epoxide reacts poorly with DNA (McLean & Dutton, 1995; Guengerich et al, 
1998; Iyer et al, 1994). The overall contribution of these enzymes to AFB1 metabolisms in 
vitro depends on the affinity of the enzyme but in vivo it also depends on expression levels 
in human liver where CYP 3A4 is predominant. Expression of CYP 1A1/2 and 3A4 in liver 
tissues of hepatocellular carcinoma cases and controls was detected and their relationship to 
HBV and AFB1-DNA adducts was also investigated (Pfeifer et al, 1993). For CYP 3A4, in 
contrast to control tissues, there was a significant association with AFB1-DNA adducts in 
tumor and adjacent non-tumor tissues in patients with HCC. Human beings show large 
interindividual variations in metabolism activities that lead to different susceptibilities to 
the genotoxic actions of carcinogens (Zhang et al, 2000). 
A model using human liver epithelial cell lines stably expressing cytochrome P450 cDNA 
revealed that CYP 1A2 and CYP 3A4 both contribute to the formation of AFB1-induced 
p53 mutation whereas CYP 2A6 does not appear to play a significant role (Macé et al, 
1997). In an in vitro study, inhibition of CYP 1A2 and CYP 3A4 by oltipraz, a drug which 
has been reported to inhibit AFB1 activation in human hepatocytes, was shown (Langouët 
et al, 1995). 
AFB1 can also be metabolized by NADPH-dependent reductase into a carcinogenic 
metabolite aflatoxicol (AFL) (Salhab & Edwards, 1977; Wong & Hsieh, 1976). AFL acts as a 
reservoir of AFB1, prolonging its lifetime in body, as it can be reconverted to AFB1, which 
then can be further metabolized. Formation of AFL does not decrease the toxicity of AFB1 
because it can also bind to DNA and is as potent carcinogen like AFB1 (Bailey et al, 1994). 
Glutathione S-transferase (GST) is a family of conjugation enzymes involved in the 
metabolism of exogenous and endogenous lipophilic compounds for their excretion and 
detoxification. For AFB1, the detoxification pathway is via GST-mediated conjugation with 
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reduced glutathione (GSH) to form AFB1 exo- and endo-epoxide GSH conjugates 
(Guengerich et al, 1998; Raney et al, 1992; Johnson WW, 1997a). Members of the GST family, 
such as GST-μ (GSTM1) and GST-θ (GSTT1), are important candidates for involvement in 
susceptibility to AFB-associated HCC, because they may regulate an individual’s ability to 
metabolize the ultimate carcinogen of aflatoxin, the exo-epoxide (Johnson WW, 1997a). 
Epidemiological studies have suggested that genetic polymorphisms in AFB1 metabolizing 
enzymes are factors in individual susceptibility to aflatoxin-related HCC (McGlynn et al, 
1995; Chen et al, 1996b). GSTM1 genotype can be categorized into two classes: the 
homozygous deletion genotype (GSTM1null genotype) and genotypes with one or two 
alleles present (GSTM1 non-null genotype); GSTT1 can also be deleted (Pemble et al, 1994; 
Rebbeck et al, 1999). Carriers of GSTM1 and GSTT1 homozygous null genotypes lack of the 
corresponding enzyme activities (Pemble et al, 1994). Chen et al (1996b) documented a 
biological gradient between serum AFB1-albumin adduct levels and HCC risk among 
chronic HBsAg carriers who had null GSTM1 and GSTT1 genotypes but not among those 
who had non-nullgenotypes in a Taiwan population. Wild et al (2000) reported an 
association between the GSTM1 null genotype and AFB1-albumin adducts in a Gambian 
population, although the association was restricted to people who were not infected with 
HBV. The effect of aflatoxin exposure on HCC risk was also more pronounced among 
chronic HBsAg carriers with the GSTT1 null genotype than those who were non-null (Sun et 
al, 2001). Based on the above studies conducted in different places and others not reviewed, 
whether or not there are interactions among AFB1, HBV infection and GSTs genotypes in 
the development of HCC is still controversial. 
2.2 Damage to DNA  
The main genotoxic product of AFB1 metabolites is AFB1-exo-8, 9-epoxide, an unstable 
metabolite which reacts with DNA, and forms adducts with a yield of 98% (Johnson & 
Guengerich, 1997). This reactivity is 1000-fold greater than that of its endo-isomer (Iyer et al, 
1994). AFB1-exo-epoxide can intercalate between the bases in DNA, and can form covalent 
bonds with DNA by electrophilic attack on the N7 position in guanines, leading to the 
formation of the adduct 8, 9-dihy-dro-8-(N7-guanyl)-9-hydroxyaflatoxin B1 (AFB1-N7-Gua). 
This adduct is fairly unstable due to a positive charge on the imidazole ring. As a result, 
AFB1-N7-Gua adducts undergo processing reactions that include either depurination to 
form an apurinic (AP) site, or opening of the imidazole ring to form a more stable, AFB1–
formamidopyrimidine (AFB1–FAPY) adduct (Smela et al, 2001). It has been proposed that 
AFB1 can also cause DNA damage through production of reactive oxygen species (Petitjean 
et al, 2007). AFB1-DNA bulky adducts, including AFB1-N7-Gua and AFB1–FAPY, are 
repaired mainly by Nucleotide Excision Repair (NER) (Bedard & Massey, 2006) but all 
AFB1-DNA adducts are not repaired with the same efficiency. The AP site is repaired by 
Base Excision Repair (BER) (Bedard & Massey, 2006). AFB1-induced DNA lesions that 
escape DNA repair can result in mutations (Smela et al, 2001). AFB1-N7 -Gua, AFB1-FAPY 
and AP sites are all candidate precursors of mutations, predominantly induce G-T 
transversions. 
As this is the pathway of its toxicological effects, the two most extensively studied 
biomarkers are the urinary aflatoxin N-7-guanine adduct, which results from AFB1 reaction 
with DNA, and aflatoxin-lysine adduct, which is obtained by digestion of the aflatoxin–
albumin adduct occurring in serum (Shephard, 2009). Early experimental studies around 
1980 demonstrated that the major aflatoxin-nucleic acid adduct, AFB1-N7-Gua, was excreted 
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exclusively in the urine of exposed rats (Bennett et al, 1981; Egner et al, 2006). The serum 
aflatoxin-albumin adduct was also examined as a biomarker of exposure because the longer 
half-life of albumin would be expected to integrate exposures over longer time periods, i.e., 
months instead of days. Studies in experimental models found that the formation of 
aflatoxin-DNA adducts in liver, urinary excretion of the aflatoxin-nucleic acid adduct, and 
formation of the serum albumin adduct were highly correlated events (Groopman, 1994).  
2.3 AFB1 inducing p53 mutaion (G-T transversions) 
AFB1 covalently binds to guanine and cytosine residues of DNA both in vivo and in vitro 
and forms AFB1-DNA adducts, it also forms RNA and protein adducts impairing DNA, 
RNA and ultimately protein synthesis (Santella et al, 1998; Meneghini & Schumacher, 1977; 
Amstad & Cerutti, 1983). The presence of AFB1-DNA adducts can contribute to genetic 
alterations involved in the development of HCC. In 1977, Lin et al (1977) reported that 
adduct formation by metabolically activated reactive intermediates with hepatocyte DNA 
could lead to mutations in the host genome. The p53 tumor suppressor gene is the most 
frequently mutated gene in human cancers. Two groups found at the same time, that 
mutations of the p53 gene on chromosome 17 are frequent in HCC and a point mutation at 
the third position of codon 249 resulting in a G:C to T:A transversion was common in HCC 
tissues which were collected in China and Africa (Hsu et al, 1991; Bressac et al, 1991). 
This mutation is present in up to 50% of patients with HCC who are indigenous to 
geographic regions with high exposure to AFB1(Bressac et al, 1991; Coursaget et al, 1993; 
Hsu et al, 1991; Ming et al, 2002). In contrast, it is absent in patients with HCC from regions 
with low exposure to AFB1 as well as in cancers other than HCC(Aguilar et al, 1994; Challen 
et al, 1992). The mutant allele is defined as R249S and the mutant protein as p.R249S. R249S 
accounts for more than 90% of TP53 mutations found in HCC cases from regions with high 
aflatoxin exposure levels, including Qidong in China and several sub-Saharan African 
countries. This percentage drops to around 30–40% in Taiwan and Hong Kong, where 
aflatoxin exposure levels are considered to be moderate. Among HCCs from low exposure 
regions, such as the United States and Japan, R249S only accounts for less than 6% of TP53 
mutations(Petitjean et al, 2007).  
This hot spot mutation in HCC from regions with high levels of dietary aflatoxins links this 
genetic change to exposure to aflatoxins. In recent years, the p53 codon 249 mutation has 
also been detected in plasma or serum DNA of HCC patients(Kirk et al, 2000; Jackson et al, 
2001; Kuang et al, 2005). This mutated DNA may serve as a biomarker of exposure to AFB1 
and for detection of early HCC(Jackson et al, 2001). 
2.4 P53 mutation in HCC 
The crystal structure of the wild-type p53 core domain in complex with DNA reveals that 
the arginine at position 249 provides four essential bridges to other residues in the L2 and 
L3 loops of the DNA-binding surface, but does not make direct contacts with DNA(Cho et 
al, 1994). Replacement of the arginine by a serine thermodynamically destabilizes the core 
domain and impairs its DNA-binding capacity(Bullock et al, 2000). Nuclear Magnetic 
Resonance (NMR) showed that the general structure of p.R249S core domain was similar to 
that of wild-type p53, but that the mutant demonstrated local structural distortion around 
position 249 in the L3 loop, with increased flexibility of the beta-sandwich scaffold(Friedler 
et al, 2004). The presence of a serine at position 249 induces a reorientation of M243. In the 
wild-type core domain, M243 is exposed to solvent when the protein is not bound to DNA 
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but is buried within at the interface between p53 oligomers when complexed with target 
DNA. In T-p53C-R249S, M243 displaces M246 from its buried location within a hydrophobic 
pocket of the zinc-binding region, leading to the formation of a short alpha-helix and a local 
conformational change that displaces the DNA-contact residue R248. This effect may explain 
the loss of the DNA-binding capacity of p.R249S. 
p.R249S has lost DNA-binding and transactivation capacities towards most, if not all, 
promoters that contain p53 consensus binding sequence. In yeast assays, its residual activity 
towards p53-dependent promoters is of less than 20% of that of wild-type p53, similar to 
most other ‘‘hotspot” p53 mutants. At biological level, Ponchel and colleagues(1994) have 
reported an increase in colony formation but not of tumorigenicity in nude mice upon 
transfection of R249S in Hep3B (p53-null hepatoblastoma cells). Using non-immortalized 
human epithelial cells, Schleger and colleagues (1999) found that p.R249S expression 
increased the size but not the number of colonies in clonogenicity assays, but did not 
prolong the lifespan of the cells. Two studies have addressed the effects of transgenic 
expression of the murine homologous p.R246S in mouse liver. Yin and colleagues (1998) 
have reported enhanced cell cycle activity in the liver due to an increased entry into G1 
phase. Thus, none of the above mechanisms provide a convincing functional explanation for 
the apparent selection of p.R249S in aflatoxin-induced HCC. 
Tumor-derived p53 mutant proteins contribute to carcinogenesis through three overlapping 
mechanisms (Gouas et al, 2010): loss of wild-type p53 trans-activation function (loss of 
function); capacity to inhibit the activity of wild-type p53 (dominant-negative effect) and 
possible ‘gain-of-function’ effects, by which mutant proteins have acquired new, pro-
oncogenic properties (Brosh & Rotter, 2009; Oren & Rotter, 2010). Several mechanisms 
underlying such gain-of-function effects have been described, including: transactivation of 
gene enhancing proliferation, inhibiting apoptosis or chemoresistance or increasing 
invasiveness, inflammation and angiogenesis (Brosh et al., 2009); interaction with various 
proteins, in particular TAp63 and TAp73, the products of two genes related to TP53 that exert 
differentiation and growth suppressive effects during development and morphogenesis 
(Bergamaschi et al, 2003; Gaiddon et al, 2001; Marin et al, 2000; Strano et al, 2002). It is not clear 
whether p.R249S exerts such gain-of-function effects which needs further studies. 
2.5 Others changes 
Moreover, it has been recently demonstrated that AFB1-albumin adducts in patients with 
HCC correlate significantly with the presence of plasma DNA hypermethylation and 
mutations in the p16 and p53 tumor suppressor genes (Zhang et al, 2006). AFB1-induced 
HCC in Fischer 344 rats showed activating mutations in codon 12 of K-ras but in human 
HCC, the incidence of point mutation of K-ras and N-ras oncogenes was low (Tsuda et al, 
1989). In an in vitro study, AFB1 interfered with the molecular mechanisms of cell cycle 
regulation (Ricordy et al, 2002). Gursoy-Yuzuqullu (2011) showed that genotoxic doses of 
AFB1 induce an incomplete and inefficient checkpoint response in human cells. This 
defective response may contribute to the mutagenic and carcinogenic potencies of aflatoxins. 
AFB1 also induced mitotic recombination (Stettler & Sengstag, 2001) and minisatellite 
rearrangements (Kaplanski et al, 1997). Mitotic recombination and genetic instability may 
therefore be alternative mechanisms by which aflatoxin contributes to genetic alterations in 
HCC (Wild & Turner 2002). 
Long and colleagues(2009) report that there were interactions between the genetic 
polymorphism of XPD codon 751 and AFB1-exposure years, and imply that this 
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polymorphism may have functional significance in HCC induced by AFB1.While XPD 
protein, encoded by XPD gene, is a DNA-dependent ATPase/helicase that is associated with 
the TFIIH transcription-factor complex, and plays a role in NER pathway. During NER, XPD 
participates in the opening of the DNA helix to allow the excision of the DNA fragment 
containing the damaged base (Benhamou & Sarasin, 2002; Manuguerra et al, 2006). These 
results suggest that the genotypes of XPD with codon 751 Gln alleles may increase the risk 
of AFB1-related HCC and the NER pathway may play an important role in the mechanism 
of action of this genotoxin. 
3. Interaction between AFB and HBV in HCC 
The marked worldwide heterogeneity of HCC incidence in HBV-endemic regions might 
be related, at least in part, to aflatoxin exposure (Yu &Yuan 2004; Yuen et al, 2009; Lodato 
et al, 2006). It should be stressed that areas with high exposure to AFB1 are also 
characterized by a high prevalence of HBV infection. AFB1 is independent of the risk 
conferred by HBV, however concomitant exposure to both HBV and AFB1 markedly 
increases the risk of HCC. Ross et al (1992) formerly demonstrated a synergistic 
interaction between HBV and AFB1 in the development of liver cancer. Subsequently, Sun 
et al (1999) followed a cohort of Chinese men with chronic HBV for 10 years and found 
that the relative risk of HCC was significantly increased in subjects with detectable AFM1 
levels. Aflatoxin exposure in association with HBV infection induces a 60-fold increase in 
risk of HCC(RR: 59.4, 95% CI: 16.6-212.0), while aflatoxin alone increases the risk 
fourfold.( Yu &Yuan 2004; Ming et al, 2002; Turner et al, 2002). In a case-control study in 
The Gambia, the codon 249ser mutation was examined in the plasma of HCC cases, 
cirrhosis patients and controls. The presence of both the codon 249ser mutation and HBV 
infection was associated with an OR = 399 (95% CI: 48.6–3270) (Kirk et al, 2004; Kirk et al, 
2005). HBV transgenic mice overexpressing HBsAg in the liver showed more HCC than 
non-transgenic littermates when exposed to AFB1 (Sell & Heim, 1991). 
Aflatoxin exposures multiplicatively increase the risk of liver cancer in people chronically 
infected with hepatitis B virus (HBV), which illustrates the deleterious impact that even low 
toxin levels in the diet can have on human health (Qian et al, 1994; Ross et al, 1992; Wang LY 
et al, 1996). Ghebranious and Sell (1998) have investigated the induction of HCC in p.R246S 
transgenic mice: they found that the presence of p.R246S enhanced aflatoxin-induced 
formation of liver tumor in conjunction with a HBsAg transgene.  
Recently, a large-scale quantitative analysis of TP53 mutations in the serum of healthy 
individuals from The Gambia, a country with high aflatoxin exposure levels and endemic 
for HBV infection, has been performed. The study revealed the presence of R249S DNA in 
the serum or plasma of apparently healthy subjects, with a seasonal variation that 
recapitulated the known variation in exposure to aflatoxin. Moreover, the presence and 
mean concentrations of R249S DNA in the plasma or serum were significantly associated 
with HBV carriage, with 44% of carriers showing detectable levels of the mutation compared 
to only 24% of non-carriers. These results are consistent with the hypothesis that HBV 
infection may specifically contribute to the acquisition and/or the retention of R249S 
mutation in hepatocytes (Gouas et al, 2009). 
However, the biology underlying this statistical interaction is not fully understood. Several 
lines of evidence suggest that HBV infection may enhance the mutagenic effects of AFB1. 
First, the presence of the virus may interfere with AFB1 metabolism. The expression of 
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CYP450 enzymes that metabolize AFB1 is increased in HBsAg-transgenic mice (Kirby et al, 
1994). Moreover, Gambian children and adolescents chronically infected with HBV show 
higher concentrations of AFB1 adducts than uninfected individuals (Kew, 2003). Second, 
viral replication and chronic inflammation due to infection induces oxidative stress in 
hepatocytes, which may contribute to the mutation load at codon 249 (Hussain et al, 1994) 
.Third, HBV may also promote these mutations through indirect mechanisms, e.g. by 
inducing chronic inflammation which, in turn, increases hepatocyte turnover rate and the 
risk of acquisition of a mutation such as R249S. Another possible mechanism of interference 
between HBV and mutagenesis at codon 249 may occur at the level of cellular DNA repair. 
AFB1–DNA adducts, in particular, AFB1-N7-Gua and AFB1-FAPY, are repaired through the 
NER pathway. The viral antigen HBx can decrease NER efficiency, probably through 
physical interaction with wild-type p53 and/or with the components of the NER machinery, 
such as XPB and XPD DNA helicases (Jia et al, 1999). The inhibition of NER by HBx may 
therefore lead to the persistence of AFB1-DNA adducts, which increases the risk for 
mutations. However, this mechanism does not account for the specific retention of R249S, 
unless some form of sequence-specificity in preferential repair of DNA at other positions 
than the third base of codon 249 is concerned. The high rate of R249S mutation may also be 
the consequence of the fact that this mutant provides some kind of selective advantage to 
infected liver cells. This may lead to the clonal expansion of p.R249S-expressing hepatocytes 
and may increase the probability for further accumulation of other cancer-prone mutations. 
This property may be due to a special capacity of p.R249S to form complexes with selected 
viral antigens. It has been reported that the HBx protein physically associates with p53 and 
apparently blocks its normal function in vitro and in vivo (Feitelson et al, 1993; Wang XW et 
al, 1994). In agreement with this view, in mice carrying HBx transgene, the X protein may 
bind to p53 and induce its retention into the cytoplasm, thus functionally inactivating its 
function (Ueda et al, 1995; Lin Y et al, 1997). Whether this interaction is of relevance for 
mutant p53, and in particular for p.R249S, is not clear. Of note, those HBx transgenic mice 
have a higher levels of G: C–T:A transversions induced by AFB1 than AFB1-exposed wild-
type mice (Madden et al, 2002).  
There maybe exists other mechanisms, including the predisposition of HBV-infected 
hepatocytes to aflatoxin induced DNA damage; an increase in susceptibility to chronic HBV 
infection in aflatoxin-exposed individuals; and oxidative stress exacerbated by co-exposure 
to aflatoxins and chronic hepatitis infection. Some epidemiological studies have clearly 
shown that two factors of importance in determining the risk of HCC in the natural history 
of HBV infection are the age at primary infection and the presence of serum HBeAg or HBV 
DNA, biomarkers of active viral replication, in patients with chronic active hepatitis (Yang 
et al, 2002). In addition, hepatitis B virus X (HBx) protein affects various cellular functions 
relevant to cancer development, namely p53 and oxidative DNA damage (Hussain et al, 
2007). This correlation may be indicative of AFB1 exposure itself inducing oxidative stress, 
HBV could predispose hepatocytes to the carcinogenic action of aflatoxins. For example, 
human liver epithelial cells, expressing wild-type p53 and transfected with HBx gene were 
more sensitive to the cytotoxic action of AFB1-8, 9-epoxide than were the parent cells (Sohn 
et al, 2000). The HBx expressing cells were also more prone to apoptosis and to induction of 
mutations at codon 249 of the p53 gene. Aflatoxin exposure may alter the effects of the 
hepatitis virus infection, perhaps affecting susceptibility to infection or viral replication. 
HepG2 cells transfected with re-circularised HBV and treated with AFB1 showed a 2-3-fold 
increase in HBsAg at 96 hours post-treatment (Banerjee et al, 2000). DNA damage can also 
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increase viral DNA integration into the host genome (Dandri et al, 2002) and it is possible 
that AFB1 could exert this effect directly, or indirectly via the oxidative stress mentioned 
above. In addition, the recent study in Guangxi, China (Xu et al, 2010) found additive effects 
of HBV BCP mutations and high serum AFB1-lysine adduct level on the risk of developing 
HCC. 
A recent study provided the first evidence that cirrhosis may play a contributory role in the 
pathogenesis of AFB1-induced HCC (Jiang et al, 2010). Kuniholm (2008) and co-workers 
used an ultrasound-based method to diagnose the presence of cirrhosis in 97 black Africans. 
A score of at least 7 out of a possible 11 points on the ultrasound-based scale was the 
criterion for the diagnosis of cirrhosis. This method has 77.8% sensitivity and 92.5% 
specificity in comparison with liver biopsy in identifying cirrhosis in HBV-infected patients 
(Lin DY et al, 1993; Hung et al, 2003). Three hundred and ninety seven individuals with no 
evidence of liver disease and a normal serum AFB1 concentration served as controls. Long-
term exposure to AFB1 was assessed in the patients with cirrhosis and the controls on the 
basis of two observations: A history of lifetime groundnut (peanut) intake or the finding in 
the serum of a genetic marker of heavy exposure to AFB1, the 249 ser p53 mutation. An 
increased relative risk of cirrhosis development of 2.8 (95% confidence interval 1.1-7.7) was 
calculated using a history of life-time dietary intake of groundnuts as the criterion for 
significant exposure, and of 3.8 (95% confdence interval 1.5-9.6) using the finding of the 249 
ser p53 mutation in serum as the criterion, allowing for the possible confounding effect of 
HBV and HCV infection in each instance.  
4. Conclusion 
Further understanding of the interaction of HBV infection, genetic variation and exposure to 
environmental chemical carcinogens will help to elucidate mechanisms of human 
hepatocarcinogenesis and develop more effective strategies for HCC prevention. At present, 
simple, low-technology, and inexpensive practices can result in a striking decrease in 
exposure to AFB1.  
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